GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Natco Pharma Ltd (BOM:524816) » Definitions » Price-to-Owner-Earnings

Natco Pharma (BOM:524816) Price-to-Owner-Earnings : 19.03 (As of May. 30, 2024)


View and export this data going back to 1995. Start your Free Trial

What is Natco Pharma Price-to-Owner-Earnings?

As of today (2024-05-30), Natco Pharma's share price is ₹1040.90. Natco Pharma's Owner Earnings per Share (TTM) ended in Mar. 2024 was ₹54.69. It's Price-to-Owner-Earnings for today is 19.03.


The historical rank and industry rank for Natco Pharma's Price-to-Owner-Earnings or its related term are showing as below:

BOM:524816' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 16.15   Med: 66.79   Max: 1737.5
Current: 18.88

During the past 13 years, the highest Price-to-Owner-Earnings of Natco Pharma was 1737.50. The lowest was 16.15. And the median was 66.79.


BOM:524816's Price-to-Owner-Earnings is ranked worse than
53.96% of 417 companies
in the Drug Manufacturers industry
Industry Median: 26.99 vs BOM:524816: 18.88

As of today (2024-05-30), Natco Pharma's share price is ₹1040.90. Natco Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ₹77.30. Therefore, Natco Pharma's PE Ratio for today is 13.47.

As of today (2024-05-30), Natco Pharma's share price is ₹1040.90. Natco Pharma's EPS without NRI for the trailing twelve months (TTM) ended in was ₹77.30. Therefore, Natco Pharma's PE Ratio without NRI for today is 13.47.

During the past 13 years, Natco Pharma's highest PE Ratio without NRI was 89.89. The lowest was 11.79. And the median was 28.83.


Natco Pharma Price-to-Owner-Earnings Historical Data

The historical data trend for Natco Pharma's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Natco Pharma Price-to-Owner-Earnings Chart

Natco Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 61.95 1,305.62 - 16.15 17.40

Natco Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.15 - - - 17.40

Competitive Comparison of Natco Pharma's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Natco Pharma's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Natco Pharma's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Natco Pharma's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Natco Pharma's Price-to-Owner-Earnings falls into.



Natco Pharma Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Natco Pharma's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1040.90/54.69
=19.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Natco Pharma  (BOM:524816) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Natco Pharma Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Natco Pharma's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Natco Pharma (BOM:524816) Business Description

Traded in Other Exchanges
Address
Road No. 2, NATCO House, Banjara Hills, Hyderabad, TG, IND, 500034
Natco Pharma Ltd is a major drug manufacturing company. Natco aims to make specialty medicines accessible to all by manufacturing niche pharmaceutical products backed by its research and development capabilities. While the vast majority of the company's revenue is generated in India, the company looks internationally for growth opportunities. The company maintains a presence in Oncology and Hepatology treatment areas. Natco's active pharmaceutical ingredient segment APIs forms a core part of the company's business. The company operates in two different business segments: pharmaceuticals and agrochemicals. Within the pharma business segment, the company drives its sales through Finished Dosage Forms and Active Pharmaceutical Ingredients.

Natco Pharma (BOM:524816) Headlines

No Headlines